Results 111 to 120 of about 4,367,374 (298)

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold   +12 more
wiley   +1 more source

Effective Databases for Text & Document Management

open access: yesIssues in Science and Technology Librarianship, 2004
Jeff Alger
doaj   +1 more source

El catàleg d'arquitectura del Centre de Documentació de Projectes d'Arquitectura de Catalunya

open access: yesBiD: Textos Universitaris de Biblioteconomia i Documentació, 2005
Es presenta el Centre de Documentació de Projectes d’Arquitectura de Catalunya (CDPAC) de la Universitat Politècnica de Catalunya (UPC), que desenvolupa un sistema catalogràfic informatitzat per a l’emmagatzematge, la cerca i la visualització per ...
Pouplana, Xavier, Poves, Lluís
doaj  

SPG4 and Dementia: Expanding the Clinical Spectrum

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Hereditary spastic paraplegia (HSP) is a group of disorders characterized by progressive spasticity and lower limb weakness, with mutations in SPG4/SPAST being the most common cause. Detailed studies and clinical and molecular comparisons across different populations are missing.
Emanuele Panza   +19 more
wiley   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Prodromal Lewy Body Disorder Features in REM Sleep Behavior Disorder With Biomarker‐Defined Synucleinopathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal state for Lewy body disorders and exhibits biological heterogeneity that may influence clinical expression and progression. We examined clinical features in individuals with iRBD and biomarker‐defined synucleinopathy.
Daniel Weintraub   +24 more
wiley   +1 more source

Durative Events in Active Databases [PDF]

open access: yes, 2004
Active databases are DBMS which are able to detect certain events in the environment and trigger actions in consequence. Event detection has been subject of much research, and a number of different event specification languages is extant.
Augusto, Juan Carlos   +3 more
core   +1 more source

Retrieving and discovering new knowledge from documents' abstracts in scientific databases: Proposing a query-based abstractive summarization model

open access: yesInternational Journal of Information Management Data Insights
Current search engines for Knowledge Retrieval (KR) and Knowledge Discovery (KD) do not effectively utilize scientifically validated documents, especially those indexed in scientific databases.
Neda Abbasi Dashtaki   +3 more
doaj   +1 more source

Informatics Solutions for Prosumers connected to Smart Grids [PDF]

open access: yesDatabase Systems Journal, 2015
This paper gives a brief overview about electricity consumption optimization based on consumption profiles of electricity prosumers that are connected to smart grids.
Simona Vasilica OPREA
doaj  

Documentation Production database

open access: yes, 2018
Documentation of the structure of the Production Database by Adlib.
openaire   +1 more source

Home - About - Disclaimer - Privacy